Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Kidney Neoplasms × Etoposide × Clear all

Phase

Phase 2 3 Phase 3 2 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 16 Small Cell Lung Carcinoma 15 Lymphoma, Large B-Cell, Diffuse 14 Lymphoma 14 Leukemia, Myeloid, Acute 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Lymphoma, Non-Hodgkin 11 Leukemia 10 Lymphoma, Mantle-Cell 9 Lymphoma, Follicular 9 Lung Neoplasms 9 Carcinoma, Non-Small-Cell Lung 7 Burkitt Lymphoma 6 Lymphoma, Large-Cell, Immunoblastic 5 Lymphoma, B-Cell 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Recurrence 4 Lymphoma, Large-Cell, Anaplastic 4 Lymphoma, B-Cell, Marginal Zone 4 Waldenstrom Macroglobulinemia 3 Plasmablastic Lymphoma 3 Lymphoma, T-Cell 3 Lymphoma, Primary Effusion 3 Leukemia, Myelomonocytic, Acute 3 Leukemia, Monocytic, Acute 3 Leukemia, Megakaryoblastic, Acute 3 Leukemia, Erythroblastic, Acute 3 Immunoblastic Lymphadenopathy 3 Dendritic Cell Sarcoma, Interdigitating 3 Congenital Abnormalities 3

Interventions

pembrolizumab 6 aldesleukin 6 Cyclophosphamide 6 fludarabine phosphate 5 fludarabine 4 Nivolumab 4 durvalumab 3 Sorafenib 3 Radiotherapy 3 Filgrastim 3 Everolimus 3 Temozolomide 2 Peripheral Blood Stem Cell Transplantation 2 Isotretinoin 2 Interleukin-2 2 Interferon-alpha 2 Fluorouracil 2 Dexamethasone 2 Cyclosporine 2 Bevacizumab 2 vorolanib 1 tremelimumab 1 tocilizumab 1 talazoparib 1 sargramostim 1 poly ICLC 1 palbociclib 1 oblimersen 1 isoquercitrin 1 guadecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05384821 2026-03-18

MetroWilms

Centre Oscar Lambret

Phase 1/2 Recruiting

Kidney Neoplasms, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡